NEW YORK(GenomeWeb) – HealthTell said today that it has received a $225,000 SBIR grant from the National Institutes of Health.

The funds will support work to evaluate the effectiveness of the company's immunosignature technology in the diagnosis of brain cancer, and glioblastoma multiforme, specifically.

According to HealthTell, the company aims through the project to demonstrate its platform's ability to distinguish primary brain cancers from brain cancers arising as metastases from other sites; and to differentiate brain cancer subtypes and grades of malignant gliomas.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Germany's Project DEAL has come to an agreement with the publisher Wiley over journal access and open-access publishing, ScienceInsider reports.

Researchers uncover additional loci associated with lifespan, which the Telegraph says could be folded into a genetic test.

A Canadian panel recommends public coverage of the gene therapy Kymriah if its cost comes down, the Globe and Mail reports.

In Nucleic Acids Research this week: new accurate quantification by sequencing approach, CNV breakpoints in Plasmodium falciparum, and more.

Feb
21
Sponsored by
L7 Informatics

This webinar will provide a first-hand look at how Gradalis, a clinical-stage immunotherapy developer, is using an information management solution from L7 to streamline its research, clinical, and manufacturing operations.